Business
Lexington Biosciences Announces Results of Annual General Meeting
Lexington Biosciences Announces Results of Annual General Meeting.
About this update from Lexington Biosciences Inc
[{"type":"text","content":"\nVANCOUVER, British Columbia, July 02, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, wishes to provide the results of its recent Annual General Meeting.\n The Company is pleased to announce that all matters before the Board were approved at the Company’s Annual General Meeting (the “AGM”) held on June 28, 2018 including the re-election of all current Directors.  Immediately following the AGM, Mr. Rocco Rossi tendered his resignation in order that he could allocate more time to his other endeavours. Company CEO, Mr. Eric Willis advises, “The Company would like to thank Mr. Rossi for his commitment to the Company and wishes him well. We are currently in the process of reviewing suitable candidates to ensure the indispensable continuance of informed governance is maintained.” The public is invited to follow us on Facebook, Twitter and LinkedIn. To receive our newsletter and news alerts direct to your inbox, you can signup at any time on any of the signup opportunities or “contact” page of our website. To find out more about Lexington Biosciences, interested readers are invited to visit our website and view our video featuring principal HeartSentry inventor Dr. Jonathan Maltz, Ph.D., which provides an excellent overview of our business proposition and opportunity ahead. About Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF)Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person’s vascular endothelium - the vital innermost lining of the cardiovascular system.  Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician.  The HeartSentry core technology was developed at the University of California Berkeley over a fifteen-year R&D period involving many research studies and product iterations resulting in a portfolio of multiple pending and issued patents licensed to the company. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patien...